SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 Patients
ABSTRACT Background The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 severity.Patients and Methods This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50titers were measured in a GFP reporter-based pseudotyped virus platform. Demographic and clinical data, complete blood counts, as well as serum levels of ferritin, Dimer-D, C reactive protein (CRP), lactose dehydrogenase (LDH), and interleukin-6 (IL-6) were retrieved from clinical charts.Results The overall correlation between levels of both antibody measurements was good (Rho=0.79;P=0<0.001). SARS-CoV-2 RBD IgG and NtAb50levels in sera collected up to day 30 after the onset of symptoms were comparable between ICU and non-ICU patients (P=>0.1). The percentage of patients who exhibited high NtAb50titers (≥ 160) was similar (P=0.20) in ICU (79%) and non-ICU (60%) patients. Four ICU patients died; two of these achieved NtAb50titers ≥ 1/160 while the other two exhibited a 1/80 titer. Very weak (Rho=>0.0-<0.2) or weak (Rho=>0.2-<0.4) correlations were observed between anti-RBD IgGs, NtAb50,and serum levels pro-inflammatory biomarkers.Conclusions The data presented herein do not support an association between SARS-CoV-2 RBD IgG or NtAb50levels and COVID-19 severity..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 04. Nov. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gozalbo-Rovira, Roberto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2020.07.22.20159673 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018418740 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018418740 | ||
| 003 | DE-627 | ||
| 005 | 20230429100051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200727s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.07.22.20159673 |2 doi | |
| 035 | |a (DE-627)XBI018418740 | ||
| 035 | |a (biorXiv)10.1101/2020.07.22.20159673 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gozalbo-Rovira, Roberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 Patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Background The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 severity.Patients and Methods This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50titers were measured in a GFP reporter-based pseudotyped virus platform. Demographic and clinical data, complete blood counts, as well as serum levels of ferritin, Dimer-D, C reactive protein (CRP), lactose dehydrogenase (LDH), and interleukin-6 (IL-6) were retrieved from clinical charts.Results The overall correlation between levels of both antibody measurements was good (Rho=0.79;P=0<0.001). SARS-CoV-2 RBD IgG and NtAb50levels in sera collected up to day 30 after the onset of symptoms were comparable between ICU and non-ICU patients (P=>0.1). The percentage of patients who exhibited high NtAb50titers (≥ 160) was similar (P=0.20) in ICU (79%) and non-ICU (60%) patients. Four ICU patients died; two of these achieved NtAb50titers ≥ 1/160 while the other two exhibited a 1/80 titer. Very weak (Rho=>0.0-<0.2) or weak (Rho=>0.2-<0.4) correlations were observed between anti-RBD IgGs, NtAb50,and serum levels pro-inflammatory biomarkers.Conclusions The data presented herein do not support an association between SARS-CoV-2 RBD IgG or NtAb50levels and COVID-19 severity. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Gimenez, Estela |e verfasserin |4 aut | |
| 700 | 1 | |a Latorre, Víctor |e verfasserin |4 aut | |
| 700 | 1 | |a Francés-Gómez, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Albert, Eliseo |e verfasserin |4 aut | |
| 700 | 1 | |a Buesa, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Marina, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Blasco, María Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Signes-Costa, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Díaz, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Geller, Ron |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro, David |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 04. Nov. |
| 773 | 1 | 8 | |g year:2022 |g day:04 |g month:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jcv.2020.104611 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.07.22.20159673 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 04 |c 11 | ||